Baidu
map

JACC:高静息心率与2型糖尿病存在共同的遗传基础

2019-10-27 不详 MedSci原创

高的静息心率(RHR)常常伴有2型糖尿病(T2D)和代谢综合征,提示可能有共同的发病机制。本研究的目的旨在评估静息心率与心脏代谢疾病/T2D的遗传基础。通过英国生物数据库(n=428250)和其他相关T2D临床试验的数据,本研究发现RHR和T2D有明显的遗传相关性((r = 0.22; 95% cl: 0.18-0.26; p = 1.99 × 10-22),RHR与其他6个心脏代谢特性也存在遗传

高的静息心率(RHR)常常伴有2型糖尿病(T2D)和代谢综合征,提示可能有共同的发病机制。本研究的目的旨在评估静息心率与心脏代谢疾病/T2D的遗传基础。

通过英国生物数据库(n=428250)和其他相关T2D临床试验的数据,本研究发现RHR和T2D有明显的遗传相关性((r = 0.22; 95% cl: 0.18-0.26; p = 1.99 × 10-22),RHR与其他6个心脏代谢特性也存在遗传相关性(空腹胰岛素、空腹血糖、腰臀比、甘油三酯、高密度脂蛋白、体重指数;p<0.05)。RHR对T2D有明显的因果关系,而T2D对RHR也有弱的因果关系。转录组分析结果显示有7个基因(SMARCAD1, RP11-53O19.3, CTC-498M16.4, PDE8B, AKTIP, KDM4B和TSHZ3)参与了RHR和T2D的相关性。另外,FADS1基因参与了RHR和空腹血糖、高密度脂蛋白与甘油三酯的相关性。

研究结果显示,静息心率与心脏代谢疾病和2型糖尿病存在共同的遗传基础。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854553, encodeId=67b4185455305, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 20:26:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326379, encodeId=30d713263e912, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579030, encodeId=ab4715e90300f, content=<a href='/topic/show?id=3007990e6f0' target=_blank style='color:#2F92EE;'>#静息心率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99076, encryptionId=3007990e6f0, topicName=静息心率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=692416492771, createdName=12498761m61暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042789, encodeId=65bb1042e8935, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 27 21:26:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374497, encodeId=26533e4497cd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Oct 27 20:14:40 CST 2019, time=2019-10-27, status=1, ipAttribution=)]
    2020-03-23 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854553, encodeId=67b4185455305, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 20:26:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326379, encodeId=30d713263e912, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579030, encodeId=ab4715e90300f, content=<a href='/topic/show?id=3007990e6f0' target=_blank style='color:#2F92EE;'>#静息心率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99076, encryptionId=3007990e6f0, topicName=静息心率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=692416492771, createdName=12498761m61暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042789, encodeId=65bb1042e8935, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 27 21:26:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374497, encodeId=26533e4497cd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Oct 27 20:14:40 CST 2019, time=2019-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854553, encodeId=67b4185455305, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 20:26:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326379, encodeId=30d713263e912, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579030, encodeId=ab4715e90300f, content=<a href='/topic/show?id=3007990e6f0' target=_blank style='color:#2F92EE;'>#静息心率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99076, encryptionId=3007990e6f0, topicName=静息心率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=692416492771, createdName=12498761m61暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042789, encodeId=65bb1042e8935, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 27 21:26:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374497, encodeId=26533e4497cd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Oct 27 20:14:40 CST 2019, time=2019-10-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854553, encodeId=67b4185455305, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 20:26:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326379, encodeId=30d713263e912, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579030, encodeId=ab4715e90300f, content=<a href='/topic/show?id=3007990e6f0' target=_blank style='color:#2F92EE;'>#静息心率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99076, encryptionId=3007990e6f0, topicName=静息心率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=692416492771, createdName=12498761m61暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042789, encodeId=65bb1042e8935, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 27 21:26:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374497, encodeId=26533e4497cd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Oct 27 20:14:40 CST 2019, time=2019-10-27, status=1, ipAttribution=)]
    2019-10-27 misszhang

    谢谢MedSci提供最新的资讯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1854553, encodeId=67b4185455305, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 20:26:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326379, encodeId=30d713263e912, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579030, encodeId=ab4715e90300f, content=<a href='/topic/show?id=3007990e6f0' target=_blank style='color:#2F92EE;'>#静息心率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99076, encryptionId=3007990e6f0, topicName=静息心率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=692416492771, createdName=12498761m61暂无昵称, createdTime=Tue Oct 29 09:26:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042789, encodeId=65bb1042e8935, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Oct 27 21:26:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374497, encodeId=26533e4497cd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Oct 27 20:14:40 CST 2019, time=2019-10-27, status=1, ipAttribution=)]
    2019-10-27 thm112988

    0

相关资讯

盘点:JACC十月第4期研究一览

1.性别特异性高敏肌钙蛋白试剂盒在急性冠脉综合征诊断中的应用DOI: 10.1016/j.jacc.2019.07.082http://www.onlinejacc.org/content/74/16急性冠脉综合征在诊断、治疗和预后方面存在明显的性别差异,而高敏肌钙蛋白在诊断疑似急性冠脉综合征患者是否存在性别差异尚不清楚。本研究纳入分析了来自10家医院的疑似急性冠脉综合征患者,主要终点事件是1年后

Sci Rep:根治性膀胱切除术后不良心血管事件风险因素分析

根治性膀胱切除术时肌肉浸润性膀胱肿瘤和非浸润性膀胱肿瘤的标准治疗方法,但是也伴随着高发生率的术后并发症,包括了严重的不良心血管事件(MACE)。舒张期功能障碍与术后并发症相关。最近,有研究人员评估了围手术期风险因素,包括了与术后6个月内与MACE有关的舒张期功能障碍。研究共包括了546名经历了选择根治性膀胱切除术的患者,研究发现,根治性膀胱切除术后6个月内,43(7.9%)名患者发展为MACE。M

JACC:糖尿病伴多支冠脉病变患者的手术选择

对于糖尿病伴多支冠脉病变(CAD)患者,FREEDOM临床试验结果显示冠脉搭桥(CABG)要总体优于冠脉介入(PCI)治疗,但PCI在临床中治疗多支冠脉病变还是比较广泛。本研究的目的旨在将FREEDOM临床试验结果进行个体化分析。本研究纳入分析了FREEDOM临床试验中1900名患者,使用基于基线协变量和治疗相互作用的模型对患者术后5年主要不良心血管事件(MACE)和1年心绞痛进行评估。最终,共有

JACC:新型心源性休克风险分层预测模型

近期心血管造影与介入学会(SCAI)提出了一个新的5期心源性休克(CS)的风险分层模型。本研究的目的旨在将SCAI提出的新的风险分层方法用于心脏重症病房(CICU)患者。本研究纳入分析了梅奥诊所2007-2015年的CICU患者,并基于患者入院时的临床特征进行CS分期。最终共纳入了10004名患者,43.1%的患者有急性冠脉综合征,46.1%的患者有心衰,12.1%的患者有心脏骤停。CS分期A-E

JACC:Evolocumab单抗远期降脂效果较好

伊伏洛单抗和其他PCSK9抗体可以减少高风险患者3年内的不良心血管风险。本研究的目的旨在评估伊伏洛单抗治疗高胆固醇血症的5年疗效。 本研究将患者第一年随机分成标准治疗(SOC)组或伊伏洛单抗组(SOC+伊伏洛单抗),一年之后,患者可以全部接受伊伏洛单抗治疗,长达4年。最终,共有1255名患者在第一年被随机分成SOC组和伊伏洛单抗组,之后有1151名患者进入全部的伊伏洛单抗治疗。与SOC相比,伊伏

JACC:不同抗凝药物对房颤患者骨折风险的影响

长期服用维生素k拮抗剂(VKAs)的老年人更容易患骨质疏松,本研究的目的旨在比较和评估接受VKA治疗和直接口服抗凝剂(DOACs)房颤患者的骨质疏松风险。本研究纳入分析了37350名房颤患者,主要终点事件是髋部骨折、要骨质疏松性骨折、任何骨折、开始骨质疏松药物治疗和一个联合终点。相比于接受VKA治疗的患者,接受DOACs治疗患者的2年骨折风险要更低(3.1%vs3.8%),DOAC与更低的骨折([

Baidu
map
Baidu
map
Baidu
map